Abstract: Anti-FGFR2b antibodies and antigen-binding fragments thereof are provided herein, as are immunoconjugates comprising the same, and compositions comprising the antibodies and immunoconjugates. Also provided are methods of making and using the antibodies and immunoconjugates, such as to treat an FGFR2b-related disease or disorder. The antibodies of the disclosure bind to human FGFR2b and can block the interaction between the KGF ligand and FGFR2b.

Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating IRAK4 inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

Abstract: Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.

Abstract: The present disclosure provides for antibody or antigen-binding fragment thereof that specifically binds to human cMET and multispecific antibody or antigen-binding fragment thereof, comprising a first antigen binding domain that specifically binds a first epitope of human cMET; a second antigen binding domain that specifically binds to a second epitope of human cMET; and a third antigen binding domain that specifically binds to human EGFR; wherein the first epitope is distinct from the second epitope, or wherein the first antigen binding domain does not compete with the second antigen binding domain. The present disclosure also provides for the use of the antibodies or multispecific antibodies for treating a disease, such as cancer.

Abstract: Disclosed herein are fused bi-cyclic compounds used as Small Molecule IL-17A Modulators. Disclosed herein is the use of these Small Molecule IL-17A Modulators for the use of decreasing IL-17 activity by inhibition, and the use of such compounds for the use in the treatment of autoimmune diseases or inflammatory diseases.

Abstract: The present disclosure provides for the antibodies or antigen-binding fragment thereof that specifically binds human CD137, multispecific antibodies and antigen-binding fragments thereof that specifically bind to human GPC3 and CD137, a pharmaceutical composition comprising said antibody, and use of the antibody, multispecific antibody or the composition for treating a disease, such as cancer.

Abstract: This disclosure provides compounds containing 7-(pyrimidin-4-yl)quinolin-4(1H)-one structure, the use thereof for selectively inhibiting the activity of CDK4, and pharmaceutical compositions comprising the compounds as treatment of various diseases including cancer.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human CCR8, a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer.

Abstract: Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.

Abstract: Antibody-drug conjugate compounds comprising a linker and methods of using such compounds are provided.

Abstract: Provided herein are compounds having the following structure: or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof, wherein the substituents are as defined herein compositions comprising an effective amount of a compound, and methods for inhibiting activity of cyclin-dependent kinases.

Abstract: The present invention relates to salts of a HPK1 inhibitor (referred to as “Compound A” hereinafter), preferably citrate, and the crystalline forms thereof. The present invention also relates to the process of preparation and uses of the salts and crystalline forms of Compound A.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-xL and treating a disease associated with the undesirable Bcl-xL activity (Bcl-xL related diseases), a method of using the compounds disclosed herein for treating tumor or cancer, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including cancers.

Abstract: The present disclosure provides antigen-binding fragments thereof that bind to DXd, and use of the antibody for detection and assay of DXd.

Abstract: Disclosed herein is 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g.

Abstract: This disclosure provides compounds containing 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H)-onestructure, the use thereof for selectively inhibiting the activity of PRMT5 in cooperative with MTA in tumors bearing MTAPDEL mutation, and pharmaceutical compositions comprising the compounds as treatment of various diseases including cancer.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer. In particular, the anti-OX40 antibody of the present invention does not interfere with the binding of OX40-ligand to its receptor.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.